2-Fl-2′-Oxo-PCM (also known as 2-Fluorodeschloroketamine or 2-FDCK) is a novel dissociative substance of the arylcyclohexylamine class. It produces dissociative, anesthetic, and hallucinogenic effects when administered. It is structurally related to arylcyclohexylamines like ketamine and deschloroketamine and is reported to produce similar effects.
2-Fluorodeschloroketamine, or 2-FDCK is classed as an arylcyclohexylamine drug. Arylcyclohexylamines are named for their structures which include a cyclohexane ring bound to an aromatic ring along with an amine group. 2-FDCK contains a phenyl ring bonded to a cyclohexane ring substituted with a ketone group (cyclohexanone). An amino methyl chain (-N-CH3) is bound to the adjacent alpha carbon (R2) of the cyclohexanone ring. Additionally, the phenyl ring is substituted at R2 with a fluorine group.
2-FDCK is named for containing a fluorine substitution at its phenyl ring rather than the chlorine which is found in ketamine.
2-Fluorodeschloroketamine is thought to act as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually this substance’s equivalent of the “K-hole.”